Evotec reported a nearly 20% decline in revenue for the first half of 2026, alongside a sharp drop into negative adjusted EBITDA, signaling worsening fundamentals. Confidence in management's future targets has diminished, leading to a valuation based solely on current performance without credit for future growth. Despite strong liquidity and some commercial progress, profitability remains elusive and turnaround timelines have been extended. The stock is considered a speculative buy at €18 per share, but investors should expect slow gains and elevated risks.
Evotec's market context includes a nearly 20% revenue decline in H1 2026 and a shift to negative adjusted EBITDA, reflecting challenges in profitability and extended turnaround timelines. For readers following the US health sector, here is Pluang's market snapshot as of Sep 21, 2026 11:31 WIB: out of 92 priced health-sector stocks, 48 rose and 44 fell. Notable movers include FLNA (Cassava Sciences Inc) with a 6.11% gain and ENVB (Enveric Biosciences Inc) up 6.04%, while XRAY (DENTSPLY SIRONA Inc) declined by 5.92%.
Shibarium has fixed its reported blockchain reorganization (reorg) issue as of September 19, 2026, resolving a key network disruption. However, the decentralized RPC (dRPC) migration and other infrastructure upgrades remain incomplete, with no set de...
Neutrl has opened redemptions for its NUSD stablecoin as the on-chain exchange rate approaches $0.51. This move allows holders to redeem their tokens, potentially stabilizing liquidity and market confidence. The redemption availability is significant...
US spot Bitcoin ETFs experienced significant inflows and outflows over five trading days, starting with $159.9 million inflows on Sept. 14, followed by $746.3 million in withdrawals over the next two days. However, demand returned strongly with $592....
X has filed a lawsuit in England against two named individuals and unidentified operators, accusing them of manipulating engagement across Bitcoin-focused accounts to fraudulently earn at least £207,384 through its Creator Revenue Sharing program. Th...
The iShares US Small Cap Value Factor ETF (SVAL) remains rated as Hold due to its portfolio's heavy financial sector exposure and a strong 6.8% earnings yield, which is 1.7 times higher than the broader market ETF IVV. However, the fund shows persist...
